NCT01510626View on ClinicalTrials.gov

Omalizumab With Oral Food Immunotherapy With Food Allergies Open Label Safety Study in a Single Center

PHASE1CompletedINTERVENTIONAL
Enrollment

35

Participants

Timeline

Start Date

November 30, 2011

Primary Completion Date

April 30, 2014

Study Completion Date

December 31, 2015

Conditions
Immune System Diseases
Interventions
DIETARY_SUPPLEMENT

Food proteins

Food proteins

DRUG

Omalizumab

Drug

Trial Locations (1)

94305

Stanford University School of Medicine, Stanford

All Listed Sponsors
lead

Stanford University

OTHER

NCT01510626 - Omalizumab With Oral Food Immunotherapy With Food Allergies Open Label Safety Study in a Single Center | Biotech Hunter | Biotech Hunter